Christoph Gaul

USPTO Granted Patents = 14 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 4.5

ph-index = 3

Forward Citations = 34(Granted Patents)

Location History:

Liestal, CH (2011 - 2014)
Basel, CH (2012 - 2014)
Aesch, CH (2014 - 2017)

Company Filing History:

Sloan-kettering Institute for Cancer Research

patents

1 out of 1,521

Cornell Research Foundation Inc.

patents

where one patent can have more than one assignee

Years Active: 2011-2017

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9789118 - Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof (2017-10-17),

2. 9339501 - 17a-hydroxylase/C17,20-lyase inhibitors (2016-05-17),

3. 9029399 - [object Object] (2015-05-12),

4. 8957056 - Migrastatin analogs in the treatment of cancer (2015-02-17),

5. 8946260 - [object Object] (2015-02-03),

6. RE45173 - Inhibitors of CYP 17 (2014-09-29),

7. 8835693 - Migrastatin analogs and uses thereof (2014-09-16),

8. 8697739 - Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof (2014-04-15),

9. 8420657 - Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors (2013-04-16),

10. 8324284 - Migrastatin analogs and uses thereof (2012-12-04),

11. 8263635 - Inhibitors of CYP 17 (2012-09-11),

12. 8202911 - Migrastatin analog compositions and uses thereof (2012-06-19),

13. 8193189 - Quinoxaline derivatives as tyrosine kinase activity inhibitors (2012-06-05),

14. 7943800 - Migrastatin analogs and uses thereof (2011-05-17),

Title: Christoph Gaul: Innovator in Pharmaceutical Chemistry

Introduction

Christoph Gaul is a prominent inventor based in Aesch, Switzerland. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 14 patents. His work focuses on developing innovative compounds that have therapeutic applications.

Latest Patents

Among his latest patents, Christoph Gaul has developed bicyclic acetyl-CoA carboxylase inhibitors. This invention provides compounds of formula (IV) and their pharmaceutically acceptable salts, along with methods for manufacturing these compounds and their therapeutic uses. Another notable patent is for 17a-hydroxylase/C17,20-lyase inhibitors, which includes compounds of Formula (I) that have been found useful as inhibitors in this biochemical pathway.

Career Highlights

Christoph Gaul has worked with leading organizations in the pharmaceutical industry, including Novartis AG and the Sloan-Kettering Institute for Cancer Research. His experience in these prestigious institutions has allowed him to advance his research and contribute to significant medical advancements.

Collaborations

Throughout his career, Christoph has collaborated with notable colleagues such as Mark G. Bock and Saumitra Sengupta. These partnerships have fostered innovation and have been instrumental in the development of his patented compounds.

Conclusion

Christoph Gaul's work exemplifies the impact of innovative research in pharmaceutical chemistry. His patents and collaborations highlight his commitment to advancing medical science through the development of new therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.